Linzess safely improves bowel movement, consistency in pediatric functional constipation

Ironwood Pharmaceuticals Inc. announced positive results from its phase 3 trial that evaluated Linzess for the treatment of pediatric patients with functional constipation, according to a company press release.In a randomized, double-blind, parallel group study, 330 pediatric patients with functional constipation aged 6 to 17 years received either Linzess (linaclotide 72 mcg, AbbVie/Ironwood) or placebo. In a Healio interview exclusive, Susanna Huh, MD, MPH, head of clinical development and research for Ironwood Pharmaceuticals, said Linzess induced a “statistically significant andRead More

Related Articles